The management of retinal vein occlusion: is interventional ophthalmology the way forward?

H Shahid, P Hossain, W M Amoaku

Retinal vein occlusions (RVO) are the second most common sight threatening vascular disorder. Despite its frequency, treatments for RVO are unsatisfactory and include several that have not been tested by large, well designed, prospective, randomised controlled trials. There is also the lack of long term follow up in many of the available small uncontrolled studies, and the timings of interventions are haphazard. This review aims to evaluate the current knowledge relating to the pathogenesis, suggested treatments for the different types of RVO, and their complications. Isovaolemic haemodilution is of limited benefit and should be avoided in patients with concurrent cardiovascular, renal, or pulmonary morbidity. Evidence to date does not support any therapeutic benefit from radial optic neurotomy, optic nerve decompression, or arteriovenous crossing sheathotomy on its own. Vitrectomy combined with intravenous thrombolysis may offer promise for central RVO. Similarly, vitrectomy combined with arteriovenous sheathotomy intravenous tissue plasminogen activator may offer benefits for branch RVO. RVOs occur at significantly high frequency to allow future prospective randomised controlled studies to be conducted to evaluate the role of different therapeutic modalities singly or in combination.

Retinal vein occlusion (RVO) is the second most common retinal vascular disorder after diabetic retinopathy and is a significant cause of visual handicap. The prevalence of retinal vein occlusions has been shown to vary from 0.7% to 1.6%. In the United Kingdom retinal vein occlusions are responsible for a significant number of new blind registrations per annum and eye enucleations subsequent to neovascular complications.

There are two main types of retinal vein occlusion—central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). Our knowledge of the outcome of patients with CRVO and BRVO has been enhanced by the findings of the Central Vein Occlusion Study (CVOS) and the Branch Vein Occlusion Study groups (BVOS). According to the CVOS, the final visual acuity after CRVO depends on the visual acuity at presentation. Vision did not improve in 80% patients with vision less than 6/60 (20/200) at presentation but 65% of patients with vision better than 6/12 (20/40) maintained this level of acuity at the end of follow up.

The visual prognosis following CRVO is largely related to the residual level of venous perfusion. In ischaemic (non-perfused) CRVO the final visual acuity is 3/60 (20/400) or worse in 87% of cases, whereas for non-ischaemic cases the vision is 6/9 (20/30) or better in 57%. Additionally, the subsequent development of macular oedema and neovascularisation has adverse effects on vision. Panretinal laser photocoagulation helps to reduce the progress of neovascular complications. However, the use of grid macular laser photocoagulation to reduce macular oedema has not been found to improve visual acuity in patients with persistent macular oedema.

BRVO is more common than CRVO and has a more favourable prognosis. The BVOS reported that, overall, 50–60% patients with BRVO will maintain visual acuity of 6/12 (20/40) or better after 1 year and thereafter the natural course of BRVO remains relatively static. Visual loss following BRVO may result from macular oedema, foveal haemorrhage, vitreous haemorrhage, epiretinal membrane, retinal detachment, macular ischaemia, and neovascular complications. The BVOS demonstrated that the probability for retinal neovascularisation is significantly greater in eyes with an area of retinal non-perfusion that measures 5 disc diameters or more and that the use of laser photocoagulation is beneficial for patients who develop macular oedema or retinal neovascularisation and have visual acuities of 20/40 to 20/100.

Until recently, the management of vein occlusions has been largely dependent on the results of the CVOS and BVOS. Patients are investigated to exclude any underlying systemic or ocular risk factors and treatment is given for sight threatening sequelae. However, over the past decade more interventional therapeutic options have emerged. The new treatments are targeted at the presumed underlying mechanical and physiological factors that lead to venous occlusion (fig 1).
This review aims to put into perspective the emerging treatment options for both CRVO and BRVO and discuss whether they offer a beneficial alternative over the natural course of the disease (tables 1 and 2). A summary of the main studies described in the literature is given in tables 3 and 4.

**INTERVENTIONS FOR CRVO**

**Steroids**

The use of steroids is advocated by those who propose an inflammatory mechanism for the pathogenesis of CRVO. Systemic steroid treatment may be considered in patients with non-ischaemic CRVO with an inflammatory component. This may be particularly justified in patients with an underlying systemic vasculitic disorder or younger patients who classically tend to have papillophlebitis. In a report of two patients pulse steroid therapy was found to increase visual acuity from 3/60 (20/800) to 6/7.5 (20/25) and from 6/24 (20/80) to 6/12 (20/40).

Local injection of steroid into the vitreous limits the side effects of systemic steroid therapy and is shown to give both anatomical (as shown by optical coherence tomography) and functional (visual acuity) improvement in macular oedema following vein occlusion. Steroids may work by stabilising the blood-retina barrier. In vitro corticosteroids inhibit vascular endothelial growth factor (VEGF) expression and may thus prevent the neovascular sequelae of vein occlusion and reduce VEGF mediated retinal capillary permeability.

Intravitreal steroids, particularly triamcinolone, seem effective in treating neovascularisation and macular oedema for both ischaemic and non-ischaemic types of vein occlusion.
<table>
<thead>
<tr>
<th>Reference</th>
<th>Type of vein occlusion ischaemic or non-ischaemic</th>
<th>Study type</th>
<th>No of patients and follow up</th>
<th>Visual outcome</th>
<th>Complications and comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Osterloh and Charles 77</td>
<td>BRVO (perfusion status unknown)</td>
<td>Case report</td>
<td>1 patient, 8 months follow up</td>
<td>54 year old female, VA improved from 20/200 to 20/25</td>
<td>3 week history of BRVO</td>
</tr>
<tr>
<td>Opremcak and Bruce 74</td>
<td>BRVO where VA ↓ secondary to macular haemorrhage and oedema + ischaemia</td>
<td>Prospective non-randomised</td>
<td>15 patients, 5 months follow up (range 1–12 months)</td>
<td>Initial VA &lt; 20/70. Snellen VA equal or better in 12 of 15 patients (80%), 10/15 patients (67%) had improved postoperative VA with average of 4 lines vision gained (range 1–9 lines). 3 patients had worse VA with average 2 lines vision lost. 2 patients had surgical success and resolution of retinal haemorrhage and oedema but no VA improvement</td>
<td>Retinal vascular bleeding in 2 patients, needed needle diathermy (these patients had different anatomical configuration, venule underlying bifurcation of arteriole). Can cause NFL defect. Bleeding. Retinal detachment. Retinal tear, duration of visual symptoms 1–12 months (average 3.3 months)</td>
</tr>
<tr>
<td>Shah et al 77</td>
<td>BRVO with macular oedema</td>
<td>Case report</td>
<td>5 patients 6.5 years follow up (range 5–7 years)</td>
<td>Initial VA &lt; 20/200. In 4 out of 5 eyes (80%) VA improved to 20/30–20/70 in 1 eye, VA remained CF secondary to macular ischaemia</td>
<td>Cataract. Vitreous haemorrhage in 2/3 patients, BRVO duration 3–4 weeks</td>
</tr>
<tr>
<td>Le Rauic et al 80</td>
<td>BRVO: recent onset</td>
<td>Prospective</td>
<td>3 patients, 1 year follow up</td>
<td>Initial VA: 20/80 after 11/12 20/80 secondary to ischaemia had laser 20/80 after 10/12 20/200 secondary ischaemia had laser 20/80 after 9/12 20/200 had persistent macular oedema No benefit</td>
<td>Nil. All patients had isovolaemic haemodilution for 10 days. Occluded vein decompressed in all cases but complete capillary reperfusion seen in only in 4 eyes Largest preop duration of BRVO was 3/12</td>
</tr>
<tr>
<td>Mester and Dillinger 75</td>
<td>BRVO</td>
<td>Control v case non-randomised</td>
<td>43 patients, 23 controls 6 weeks follow up</td>
<td>VA &lt; 20/50 and macular haemorrhages + oedema or ischaemia. Mean VA ↓ from 0.16 (± 0.12) to 0.36 (± 0.25) following surgery 26 patients (60%) gained at least 2 lines of VA and 12 patients (28%) gained 4 lines VA. Only 1 patient lost 2 lines VA. All patients with improvement of 4+ lines had incomplete vein occlusion on FFA. 4 eyes with complete occlusion had worst results functionally. Macular oedema + intraretinal haemorrhage resorbed in all patients. Control group: VA ↓ from 0.23 (± 0.12) to 0.22 (± 0.16) over 6 weeks 5 eyes (20%) gained 2 + lines VA 9 patients (36%) lost 2 + lines Operated patients had slightly better functional outcome</td>
<td>Nil. All patients had isovolaemic haemodilution for 10 days. Occluded vein decompressed in all cases but complete capillary reperfusion seen in only in 4 eyes Largest preop duration of BRVO was 3/12</td>
</tr>
<tr>
<td>Cahill et al 77</td>
<td>BRVO</td>
<td>Retrospective</td>
<td>27 patients</td>
<td>29.6% had resolution of CMO and significant increase in VA. There was no improvement in VA in 2/3 eyes</td>
<td></td>
</tr>
<tr>
<td>Intravitreal triamcinolone</td>
<td>BRVO</td>
<td>Prospective comparative, non-randomised</td>
<td>10 patients, 18 controls, 8 months follow up</td>
<td>Mean VA increased significantly in the treated group. 90% of eyes gained VA and 60% had an increase in VA at least 2 lines</td>
<td>VA increased significantly only in the non-ischaemic subgroup</td>
</tr>
<tr>
<td>Jonas et al 26</td>
<td>BRVO</td>
<td>Prospective, non-randomised</td>
<td>18 patients, 16 controls, 1 year follow up</td>
<td>Final VA was better in the treated group. Final VA was 6/12 in treated and 6/24 in controls</td>
<td></td>
</tr>
<tr>
<td>Reference</td>
<td>Type of vein occlusion</td>
<td>Study type</td>
<td>No of patients and follow up</td>
<td>Visual outcome (visual acuity – VA)</td>
<td>Complications and comments</td>
</tr>
<tr>
<td>-----------------</td>
<td>------------------------</td>
<td>------------</td>
<td>-----------------------------</td>
<td>---------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Systemic steroids</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shaikh et al</td>
<td>Non-ischaemic CRVO</td>
<td>Case reports</td>
<td>2 patients</td>
<td>Event in second eye: Patient seen 5/12 post-CRVO. 1/7 post IV methylpred: VA ↑ to 20/250 from CF</td>
<td>Nil Temporary response 1 year hx of CRVO</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1/52 later VA ↑ 20/25</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3/12 later VA ↓ to 20/400</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3 years later VA 20/200</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Periocular steroid improved VA to 20/30 initially (in past)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Initial VA 20/20 RE and 20/80 LE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>60 mg pred: VA 20/40 LE at 10 days</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8/12 later VA 20/80 again</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Repeat steroid by mouth: VA ↑ to 20/60</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2/12 later: more CMO + ↓ VA now refractory to steroid</td>
<td></td>
</tr>
<tr>
<td><strong>Intravitreal steroids</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Greenberg et al</td>
<td>Haemorrhagic CRVO in 2nd affected eye with macular oedema</td>
<td>Case report</td>
<td>1 patient</td>
<td>Initial VA 20/400 LE, CF Re (LE has acute visual loss). VA 20/80 in LE 6/52 post-injection and 20/30 after 3/12. But ↓ VA 6/12 post injection however macular oedema ↓ 2nd triamcinolone injection VA 20/50 1/12 later. Macular oedema resolved after each injection (shown by OCT). Note: no effect of triamcinolone on fellow eye with longstanding CRVO.</td>
<td>Nil IOP (25% eyes) Cataract Retinal detachment, endophthalmitis. FFA showed no ischaemia initially. Rarely Rx may be necessary for visual improvement before longstanding macular oedema causes irreversible photoreceptor damage.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ip et al</td>
<td>Non-ischaemic CRVO</td>
<td>Case report</td>
<td>1 patient, 16 months follow up</td>
<td>10 months hx of ↓ VA. Initial VA 20/40 in RE VA fell to 20/200 when injection given 1 month later VA ↑ to 20/25 with resolution of macular oedema</td>
<td>Nil 4 mg triamcinolone acetonide</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ip et al</td>
<td>Ischaemic CRVO</td>
<td>Case report</td>
<td>1 patient, 8 months follow up</td>
<td>8 months hx of CRVO 3/52 post-injection, VA ↑ from 20/200 to 20/100 with ↓ macular oedema 3/12 post injection VA ↓ to 20/400</td>
<td>Nil Temporary benefit in ischaemic CRVO VA improvement less marked</td>
</tr>
<tr>
<td>Jonas et al</td>
<td>Bilateral CRVO with longstanding macular oedema</td>
<td>Case report</td>
<td>1 patient, 4 months RE follow up</td>
<td>RE: VA ↑ from 0.05 to 0.25 LE: VA ↑ from 0.125 to 0.25 Reduced leakage at macula on FFA</td>
<td>Nil RE, CRVO 2 years ago; LE, CRVO 1.5 years ago 25 mg triamcinolone into each eye 10/52 apart</td>
</tr>
<tr>
<td><strong>Intravenous thrombolysis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kohner et al</td>
<td>CRVO less than 7 days</td>
<td>Case report</td>
<td>20 patients, 1 year follow up</td>
<td>VA not significantly different between Rx + control groups Neovascular glaucoma (1 treated patient) (4 control patients). Vitreous haemorrhage (within 3/7 in 3 treated eyes; within 1 month in 4 control eyes, pre-vitreatomy era)</td>
<td>Neovascular glaucoma (1 treated patient) (4 control patients). Vitreous haemorrhage (within 3/7 in 3 treated eyes; within 1 month in 4 control eyes, pre-vitreatomy era)</td>
</tr>
<tr>
<td>Elman et al</td>
<td>CRVO (perfused)</td>
<td>Pilot study (for future randomised controlled trial)</td>
<td>96 patients, 6 months follow up</td>
<td>42% (n = 89) gained 3 + lines of vision. 37% remained stable. 21% lost 3+ lines. In eyes with 20/100 or worse pre-Rx vision (n = 32), 59% gained 3+ lines (average gain 6.4 lines) 31% stable. 4% lost 3+ lines</td>
<td>3 patients developed intraretinal bleeding. GI bleeding (1 patient). Fetal CVA (1 patient). Oozing from previous venepuncture sites or slight bruises (all patients). Inferior subretinal PE haemorrhage (1 patient). Vitreous haemorrhage with retinal detachment (1 patient). Haemorrhagic sub-RPE detachment (1 patient). 6/12 duration of CRVO HPA + aspirin HPA + aspirin + heparin HPA + aspirin + heparin + warfarin</td>
</tr>
</tbody>
</table>

**Table 4**: Summarising treatment modalities for CRVO
<table>
<thead>
<tr>
<th>Reference</th>
<th>Type of vein occlusion</th>
<th>Study type</th>
<th>No of patients and follow up</th>
<th>Visual outcome (visual acuity – VA)</th>
<th>Complications and comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intravitreal t-PA</td>
<td>CRVO</td>
<td>Prospective with no control group</td>
<td>26 patients, CRVO = 23 patients, Hemiretinal vein occlusion = 3 patients, 6 months follow up</td>
<td>CRVO: VA improved in 7/23 patients (30.4%) at 6 weeks and 8/23 (34.8%) at 6 months</td>
<td>↑ in macular oedema, vitreous haemorrhage, ↑ in size of macular haemorrhage (^{2})</td>
</tr>
<tr>
<td>Lahey et al (^{31})</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glacet-Bernard et al (^{32})</td>
<td>CRVO</td>
<td>Prospective non-comparative case series</td>
<td>15 patients, 5–21 months (mean 8 months) follow up</td>
<td>VA ↓ to 20/40 or worse, 22 of 28 patients (79%) experienced at least 1 line of visual improvement at least 1 line of visual improvement. Initial VA &lt;20/400 15 eyes (54%) ↓ 3 + lines ↓ in VA in 3/12 14 eyes (40%) had 3 + lines ↓ VA by end of follow up 10 eyes (36%) ↓ at least 5 lines 5 eyes ↓ by at least 8 lines 1 eye recovered from 20/400 preop to 20/20 post-op</td>
<td>PRP, 3 eyes for neovascularisation, TPA+ low dose heparin, TPA within 2 weeks of symptoms</td>
</tr>
<tr>
<td>Elman et al (^{33})</td>
<td>CRVO (perfused on FFA)</td>
<td>Prospective non-comparative case series</td>
<td>9 patients, &gt;6 months follow up</td>
<td>4/9 eyes (44%) had 3 + lines improvement at 6 months (average improvement 7 lines). 2 eyes had 6 or more lines loss of vision at 6 months. 3 eyes needed PRP</td>
<td></td>
</tr>
<tr>
<td>Ghazi et al (^{34})</td>
<td>CRVO</td>
<td>Prospective non-controlled study</td>
<td>12 patients</td>
<td>55% of patients with initial VA &lt;20/200 had a final visual acuity of 20/50 or better</td>
<td>Symptom duration was &lt;3 days</td>
</tr>
<tr>
<td>Intravitreal t-PA</td>
<td>CRVO</td>
<td>Prospective non-comparative case series</td>
<td>28 patients, range 3–24 months follow up</td>
<td>VA 20/400 or worse. 22 of 28 patients (79%) experienced at least 1 line of visual improvement. Initial VA &lt;20/400 15 eyes (54%) ↓ 3 + lines ↓ in VA in 3/12 14 eyes (40%) had 3 + lines ↓ VA by end of follow up 10 eyes (36%) ↓ at least 5 lines 5 eyes ↓ by at least 8 lines 1 eye recovered from 20/400 preop to 20/20 post-op</td>
<td>Unable to catheterise vein in 1 patient. ↓ of vision after initial improvement. Intravitreal haemorrhage (\leq 2) patients. Mean duration of symptoms 26 days (range 12 hours to 7 months) Urokinase into ophthalmic artery</td>
</tr>
<tr>
<td>Intravitreal t-PA</td>
<td>CRVO + CRAO</td>
<td>Retrospective</td>
<td>26 patients, CRVO + CRAO = 9 patients, CRVO + cilioretinal AO = 3 patients, CRVO only: 14 patients, 10 months follow up range 2–24 months</td>
<td>Initial VA &lt;20/60 or CRAO in fellow eye or ↓ VA after initial improvement and if other eye lost. 6 patients had ↑ in VA within 48 hours – 4 for these were CRAO + CRVO (in latter, VA was &gt;20/50)</td>
<td>Stopping aspirin led to ↓ VA to 20/200 due to macular oedema. Visual loss &lt;30 days + urokinase VA, 20/200 IV heparin 48 hours 1000 Mw heparin 1 month, oral aspirin 3 months</td>
</tr>
<tr>
<td>Paques et al (^{35})</td>
<td>CRVO + CRAO</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ophthalmic artery fibrinolysis</td>
<td>Retrospective</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weiss and Bynoe (^{36})</td>
<td>CRVO</td>
<td>Prospective non-comparative intervention case series</td>
<td>13 patients, 1 year follow up</td>
<td>5/13 patients had ↓ VA with retinal perfusion in 24–48 hours VA returned to normal in 24–48 hours in 3 patients, within 1 week in 1 patient + 1/2 in 1 patient. 1 patient relapsed 1/2 later (repeat CRVO when heparin stopped) At end of follow up 1 had normal vision, 7 had no improvement</td>
<td>Stopping aspirin led to ↓ VA to 20/200 due to macular oedema. Visual loss &lt;30 days + urokinase VA, 20/200 IV heparin 48 hours 1000 Mw heparin 1 month, oral aspirin 3 months</td>
</tr>
<tr>
<td>Intravitreal t-PA</td>
<td>CRAO</td>
<td>Severe non-ischaemic</td>
<td>13 patients, 1 year follow up</td>
<td>5/13 patients had ↓ VA with retinal perfusion in 24–48 hours VA returned to normal in 24–48 hours in 3 patients, within 1 week in 1 patient + 1/2 in 1 patient. 1 patient relapsed 1/2 later (repeat CRVO when heparin stopped) At end of follow up 1 had normal vision, 7 had no improvement</td>
<td>Stopping aspirin led to ↓ VA to 20/200 due to macular oedema. Visual loss &lt;30 days + urokinase VA, 20/200 IV heparin 48 hours 1000 Mw heparin 1 month, oral aspirin 3 months</td>
</tr>
<tr>
<td>Intravitreal t-PA</td>
<td>CRVO</td>
<td>Severe non-ischaemic</td>
<td>11 patients, 6 years follow up</td>
<td>7 of 11 patients had slight ↓ in mean VA (p=0.006) and then remained stable throughout follow up (p&gt;0.1) not significant</td>
<td>1 patient, intravitreal haemorrhage, needing vitrectomy and PRP leading to NPL vision. Visual loss 12–72 hours (mean 32.5 hours), except 1 patient treated after 10 days for compassionate reasons. Urokinase</td>
</tr>
<tr>
<td>Reference</td>
<td>Type of vein occlusion</td>
<td>Study type</td>
<td>No of patients and follow up</td>
<td>Visual outcome (visual acuity – VA)</td>
<td></td>
</tr>
<tr>
<td>----------------------------</td>
<td>----------------------------</td>
<td>--------------------</td>
<td>------------------------------</td>
<td>---------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Opremcak et al</td>
<td>Severe haemorrhagic CRVO</td>
<td>Retrospective</td>
<td>11 patients, Average 9 months (5–12 months range)</td>
<td>All had initial VA &lt; 20/400 All had improved fundus pics (photos + FFA) Equal or better Snellen VA in 9/11 patients (82%) VA improved in 8/11 patients (73%) – average 5 lines improvement (range 3–7 lines) 7/11 patients (73%) had final VA = 20/200 5/11 patients (45%) had final VA = 20/70 2/11 patients had 20/40 final VA 2 patients had worse VA both had iris rubeosis</td>
<td></td>
</tr>
<tr>
<td>Opremcak et al</td>
<td>CRVO</td>
<td>Retrospective</td>
<td>11 patients, Average 9 months (5–12 months range)</td>
<td>Nil Potential Laceration of CRV or CRA optic nerve damage, globe perforation, retinal detachment Average duration of CRVO 4 months (range 1–7 months) Single surgeon Final VA did not correlate with duration of CRVO or presence of systemic changes Younger age of onset tended to give worse prognosis: patients with equal or worse VA had average age 54 and with improved VA 64 years</td>
<td></td>
</tr>
<tr>
<td>Garcia-Arumi et al</td>
<td>CRVO</td>
<td>Prospective case series no control group</td>
<td>51 patients, 4.5 months follow up</td>
<td>57% patients gained 1 or more line of vision, 43% patients improved in visual acuity by 2 or more lines 40% incidence of neovascularisation requiring PRP</td>
<td></td>
</tr>
<tr>
<td>Weizer et al</td>
<td>CRVO</td>
<td>Interventional case series</td>
<td>5 patients, 4.5 months follow up</td>
<td>4 patients (80%) had improved VA, 2 patients (40%) improved to 20/80 postop. In 80% disc congestion improved and intraretinal haemorrhages resolved faster than expected 41% people treated within 2 weeks had a VA of 20/40 v 23% in the late treatment group. Final retinal ischaemia was greater in the late treatment group</td>
<td></td>
</tr>
<tr>
<td>Glacet-Bernard et al</td>
<td>Central or hemiretinal vein occlusion</td>
<td>Prospective</td>
<td>142 patients, 10 months follow up</td>
<td>Early treatment gave better results</td>
<td></td>
</tr>
<tr>
<td>Hansen et al</td>
<td>Ischaemic and non-ischaemic CRVO</td>
<td>Prospective randomised controlled trial</td>
<td>19 patients (IHD + PRP) and 19 controls (PRP) 1 year follow up</td>
<td>Patients treated with IHD and PRP had a statistically significant improvement in VA compared to PRP alone Study stopped early because of treatment benefit</td>
<td></td>
</tr>
<tr>
<td>Hansen et al</td>
<td>Non-ischaemic CRVO</td>
<td>Randomised controlled trial</td>
<td>14 patients and 14 controls 1 year follow up</td>
<td>8 of 14 study patients had improved VA compared to none of the controls Mean preoperatively VA 20/160, mean postoperative VA 20/70. 6 patients improved in VA</td>
<td></td>
</tr>
<tr>
<td>Dev and Buckley</td>
<td>All with optic nerve oedema</td>
<td>Prospective</td>
<td>8 patients, 12.4 months follow up (3–27 months)</td>
<td>Significant difference between groups. Progression to ischaemia in 15 eyes (38%) 18 (20%) had neovascular complications— intravitreal, intraretinal, and subretinal neovascular membranes significantly associated with retinal ischaemia (p&lt;0.001) Immediate Subretinal haemorrhage Vitreous haemorrhage Late: Distal vein closure Fibrovascular proliferation, NVE, progressive capillary non-perfusion in 19 eyes (21%)</td>
<td></td>
</tr>
<tr>
<td>Laser chorioretinal venous anastomosis</td>
<td>Non-ischaemic CRVO</td>
<td>Retrospective consecutive series</td>
<td>91 patients, 12 months</td>
<td>Successful anastomosis in 49 eyes (54%) 84% eyes had average † VA of 4.3 lines ± 3.8 lines (range 2–20 lines) 16% had no improvement (6 eyes, 12%) or ↓ vision (2 eyes, 4%) No progression to ischaemia in eyes without anastomosis: 17 eyes (40.5%) had ↓ VA 8 (19%) had same VA 17 (40.5%) had ↓ VA Significant difference between groups. Progression to ischaemia in 15 eyes (38%)</td>
<td></td>
</tr>
</tbody>
</table>
Intravitreal steroid injection is a quick procedure that can be performed in an outpatient setting. Steroids are an option when patients with macular oedema are not eligible for or are resistant to laser photocoagulation. However, since the response appears short lived\textsuperscript{11 13 15} steroids may not be suitable as definitive treatment. The risks of steroid administration must also be considered. Raised intraocular pressure is reported to occur in up to 25\% eyes after intravitreal steroid\textsuperscript{20} and can make the eye prone to further ischaemic insult. The development of intractable glaucoma has also been reported.\textsuperscript{26} Other risks include infection, cataract, haemorrhage, and retinal detachment.

In chronic macular oedema there is a suggestion that anatomical success does not equate with functional improvement.\textsuperscript{13} Perhaps early treatment is necessary for visual improvement before longstanding macular oedema results in irreversible photoreceptor damage. Until a large case-control or randomised controlled series is available recommendations cannot be made on dosage, timing, and case selection for the use of steroids.

Anticoagulation and thrombolysis

It is postulated that dissolving the thrombus causing CRVO at the lamina cribrosa and/or preventing its reformation (through anticoagulation or antiplatelet therapy) should effectively restore retinal blood flow and visual function. Even if irreversible damage has occurred rapid restoration of normal retinal blood flow, through clot dissolution, may prevent further visual loss from the chronic complications of CRVO.

Systemic anticoagulants (such as oral aspirin, subcutaneous heparin, or intravenous thrombolysis) have not been shown to be an effective treatment for vein occlusions.\textsuperscript{27 28} In addition, their use causes unacceptable risks of intraocular, intracerebral, and gastrointestinal haemorrhage.\textsuperscript{29 30} Consequently, local routes of administration of thrombolytic agents have been investigated.

Intravitreal thrombolysis

The rationale for intravitreal administration of tissue plasminogen activator (t-PA) is that it can diffuse across the internal limiting membrane of the retina and enter the retinal circulation through capillaries damaged by breakdown of the blood-retina barrier following CRVO. The t-PA would then be transported by residual venous flow towards the lamina cribrosa, the presumed site of thrombus, to cause thrombus lysis.

Lahey et al reported that eight (34.8\%) of 23 patients achieved vision greater than or equal to 6/12 (20/40) at 3 months after intravitreal injection of t-PA. This included an eye that went from 3/60 (20/400) to 6/7.5 (20/25) and another from 1/60 (3/200) to 6/6 (20/20).\textsuperscript{31} In the CVOS, only 3.2\% of 155 eyes achieved this level of vision at 4 months. Glacet-Bernard et al also found that vision improved to at least 20/30 in 36\% eyes following intravitreal thrombolysis.\textsuperscript{32} Success was not universal. This may reflect the varying maturity of the clots at the time of intervention, as animal studies suggest that t-PA is most effective in immature clots.\textsuperscript{33} Co-existent poor retinal perfusion may limit visual improvement. Important factors that seemed to determine outcome were the type of CRVO, and the timing of intervention. However, the lack of a control group in these studies and the small patient numbers means there is insufficient material for substantive conclusions to be reached.

Complications of intravitreal thrombolysis include vitreous haemorrhage and an increase in macular oedema.\textsuperscript{11 12} It is suggested that t-PA may have lysed smaller secondary fibrin clots at the retinal capillary level that are deposited in response to the damage caused by the vein occlusion. If this occurs without the clot at the lamina cribrosa being lysed, the
retinal venous pressure remains elevated and there may be an increase in exudation which can lead to increased macular oedema. The most dramatic improvement following t-PA was seen in non-ischaemic CRVO.34,35

**Retinal venous thrombolysis**

Retinal vein cannulation allows t-PA to be delivered under direct view into the retinal vein to cause thrombolysis. After the initial report of this procedure36 Weiss and Bynoe conducted a prospective interventional case series of 28 patients with an average duration of CRVO of 4.9 months and visual acuity of 3/60 (20/400) or worse;22 of the 28 patients (79%) who underwent the procedure had better visual acuity at the final follow up examination than at baseline. Ten eyes (36%) improved by at least five lines of vision at the last follow up and five eyes improved by at least eight lines. One eye recovered from 3/60 (20/400) preoperatively to 6/6 (20/20) postoperatively. Side effects were, however, significant. Vitreous haemorrhage was seen in seven patients (25%) and one patient went on to develop a retinal detachment.

Weiss and Bynoe propose that direct venous thrombolysis provides a high local concentration of t-PA which is delivered at a high flow rate and can act to flush out the thrombus. However, the law of haemodynamics suggest that when CRVO is longstanding the t-PA would follow the path of least resistance and be flushed out of the central retinal vein via the collateral vessels that have developed with little t-PA remaining to act on the thrombus.34 However, if t-PA is injected early after onset of the vein occlusion, collateral vessels will not yet have developed and the t-PA may then reach the desired site. Further studies are needed on the optimal timing for intervention.

**Ophthalmic artery thrombolysis**

Recent advances in interventional neuroradiology have made it possible to selectively catheterise the ophthalmic artery and infuse a fibrinolytic agent close to the obstruction site.

Three studies have been reported using this novel technique in patients with CRVO.35,36 37 The internal carotid artery was catheterised via the femoral artery. An initial arteriogram was used to fashion the tip of the microcatheter in accordance with the geometry of the carotid arterial siphon and ophthalmic arterial ostium. Urokinase was then infused over 1 hour. Subsequently, all patients were given intravenous heparin for 48 hours, followed by subcutaneous low molecular weight heparin for 1 month (to inhibit coagulation on the thrombus and limit clot extension and recurrence) and oral aspirin for 3 months (to combat risk factors for atherosclerosis and prevent further thrombosis).

In a retrospective study of 26 patients (all with VA less than 6/18 (20/60)) six patients had improved vision after 48 hours, which was maintained long term in five patients.39 In a subgroup analysis, four of the six patients with visual improvement had pretreatment Funduscopic appearances suggestive of combined central retinal artery and vein occlusion. This pattern was seen in nine of 26 patients in the series. Thus, overall, four out of the nine (44%) patients with this pattern improved.

In a prospective series of five patients, three who had the features of combined central retinal artery and vein occlusion achieved full visual recovery after this intervention.40 These patients had visual loss of less than 30 days’ duration with visual acuity less than 6/30 (20/100). These patients had no capillary closure, and four of them had no macular oedema. It seems, therefore, that impairment of retinal arterial perfusion was responsible for their visual loss and minimally invasive local intra-arterial thrombolysis had a rapid beneficial effect.

Since patients with combined central retinal artery and vein occlusion were found to respond well to thrombolytics,39,40 a separate prospective study was undertaken on this group of patients.41 Eleven consecutive patients with visual loss of less than 72 hours were treated during a 6 year period. Vision improved at some point after treatment in seven of 11 patients, including six in who substantial improvement after 24–48 hours. Funduscopically showed the retinal pathology to regress over 2–4 weeks.

Complications encountered include vitreous haemorrhage which may lead to blindness.41 The haemorrhage may have resulted from rupture of ischaemic retinal vessels caused by severely impaired retinal arterial perfusion as well as a combined sudden increase in retinal venous hydrostatic pressure caused by venous thrombosis as a result of the release of arterial thrombosis by fibrinolysis. Local administration of thrombolitics avoids systemic complications or change in clotting status. There were no cases of post-procedure neurological deficit.

There is the possible requirement for long term anti-coagulation following thrombolysis. One patient had a repeat CRVO just over 1 month after thrombolysis when heparin was stopped. Similarly, stopping aspirin led to a further decrease in vision from 6/15 (20/50) to 6/60 (20/200) as a result of cystoid macular oedema.42

The local administration of thrombolytic agents is a feasible treatment for RVO but may only be beneficial in certain types of RVos. In addition, it seems appropriate to administer treatment before the thrombus becomes organised. Promising results are seen in patients with combined central retinal artery and vein occlusion. Unfortunately, the studies lack a control group and spontaneous improvement of this subgroup has been reported.42

**Isovolaemic haemodilution**

Whatever the primary cause of RVO, the obstruction causes a local increase in blood viscosity. In isovolaemic haemodilution, venesection is performed at the same time as infusion of a plasma substitute (for example, hydroxyethyl starch, dextran) so that a constant blood volume is maintained. By reducing the haematocrit level, haemodilution causes a reduction in blood viscosity and thus improves retinal blood flow and oxygen supply. Thus, it relieves retinal hypoperfusion during a critical time of occlusion and may prevent capillary closure and further retinal ischaemia. Haemodilution therapy has been shown to be an effective intervention for CRVO in a number of randomised studies. Beneficial effects have been seen with respect to visual acuity, retinal circulation times, and haemorheological parameters.43–46

Hansen et al carried out a prospective randomised trial evaluating the efficacy of combined isovolaemic haemodilution and panretinal photocoagulation (PRP) in patients with ischaemic and non-ischaemic CRVO. Patients treated with haemodilution and PRP showed a statistically significant improvement in vision compared to patients treated with PRP alone up to 1 year later. In both groups the final visual acuity was worse for ischaemic CRVO. However, the most marked improvement in visual acuity was seen in patients with ischaemic CRVO but this did not reach statistical significance as the numbers of patients were small.47

Hansen et al demonstrated a significant treatment effect with the use of isovolaemic haemodilution alone in non-ischaemic CRVO. Eight of 14 patients with non-ischaemic CRVO who were given isovolaemic haemodilution alone had improved in visual acuity compared to none of the 11 controls (p<0.01).48

The importance of early intervention was shown by Glacet-Bernard et al, who analysed 142 patients with central or
hemiretinal vein occlusion. Final visual acuity was significantly better if treatment was instituted within the first 2 weeks of vein occlusion; 41% had a final visual acuity of 20/40 or better in this early treatment group versus 23% in the late treatment group (p<0.01).46

Ischaemic change may underlie the need for early intervention. In Glacet-Bernard’s study retinal ischaemia was not significantly greater in the late treatment group at inclusion but at the end of follow up ischaemic change was significantly greater in the late treatment group. Isovaletic haemodilution thus seems to prevent retinal ischaemia and risk of conversion of non-ischaemic RVO to ischaemic RVO. 

Isovaletic haemodilution is a systemic treatment. Patients having this treatment would need to be carefully selected. It may not be suitable for patients with CCF, renal or respiratory insufficiency and anaemia. Isovaletic haemodilution alone has not been shown to prevent neovascular glaucoma or to arrest ischaemia and therefore most studies have used adjunctive laser therapy.47 48

Radial optic neurotomy

It is thought that radial optic neurotomy releases pressure in the scleral outlet compartment (the space containing the scleral canal, cribiform plate, optic nerve, central retinal artery and vein). This increases the central retinal vein lumen which in turn increases venous flow and helps clear the thrombus.

Examination of cadaveric eyes showed that the scleral outlet could be decompressed via an internal vitreoretinal approach.47 A standard three port vitrectomy is done and the intraocular pressure raised to minimise any potential bleeding. A radial optic neurotomy is done using a microvitrectinal (MVR) blade on the nasal side of the disc to avoid injury to the papillomacular bundle. The cut is radial (non-radial cuts would transect the nerve fibre layer neurons as they enter the optic nerve) and approaches the centre of the cribiform plate. 

The Radial Optic Neurotomy Study is a retrospective non-randomised pilot study of 11 consecutive patients with severe haemorrhagic CRVO.52 In the selected patient group, with visual acuity equal to or less than 3/60 (20/400), prognosis is normally poor without intervention.53 Surgical relaxation of the scleral outlet was associated with a dramatic and rapid clearing of intraretinal haemorrhages and improved retinal blood flow in all patients. Visual acuity improved in eight of the 11 patients (73%) with an average of five Snellen lines improvement. The final visual acuity did not correlate with duration of CRVO or the presence of systemic disease. A younger age of onset tended to show a poorer visual prognosis.

These impressive results have been criticised by some authors, who suggest that the use of Snellen acuity (rather than the Early Treatment Diabetic Retinopathy Study (ETDRS) acuity used in the CVO5) may have underestimated the actual presenting visual acuity, and that these patients may have had favourable natural outcomes without intervention.54 Retinal capillary non-perfusion was used as the only criterion to make the distinction between ischaemic and non-ischaemic CRVO. Unfortunately, this criterion on its own has poor reliability in making such differentiation in the early stages of CRVO.55 However, the distinction is vital in determining prognosis. Further, no visual field evaluations were undertaken in this study and as such no comment could be made on the occurrence of optic nerve damage.

More modest results are seen in a small interventional case series of five patients,56 where a 40% incidence of rubecous iridis was reported post-procedure. Similarly, modest results are reported by Garcia-Arumi et al, where 43% patients improved in visual acuity by two or more lines in an uncontrolled study.51

Potential complications include laceration of the central retinal artery or nerve, optic nerve damage, globe perforation, and retinal detachment. Visual field defects may occur because of optic nerve head ischaemia after cutting the circle of Zinn-Haller or nerve fibre transection.53 Currently, the anatomical success of the technique outnumbers functional success and prospective randomised studies are needed.

The rationale for this procedure is difficult to understand. The presence of a hypothetical bottleneck at the optic nerve head is not logical given that the difference in diameter between retrolaminar and prelaminar optic nerves could be explained by the presence of a myelin sheath. The theory would also not be able to explain the development of a hemiretinal vein occlusion.57 The central retinal vein lies temporal to the artery in the optic nerve, enclosed by a common fibrous capsule. Thus, the nasal cut in radial optic neurotomy cannot decompress the vein.54

Optic nerve sheath decompression

The rationale for optic nerve sheath decompression is that optic nerve oedema results in some degree of mechanical venous compression. This hypothesis is based on previous studies on posterior scleral ring section58 59 and the demonstration of decreased retinal vein calibre after optic nerve sheath decompression in patients with pseudotumour cerebri.57

Optic nerve sheath decompression was performed in eight patients with progressive CRVO and optic nerve oedema. The mean follow up period was 12.4 months.60 Overall, six patients improved in visual acuity. Mean preoperative vision was 6/48 (20/160) and mean postoperative vision was 6/21 (20/70). The probability of improvement in visual acuity is reported to be 75%. Non-ischaemic eyes operated on within 3 months of CRVO onset, age under 65 years, and initial visual acuity greater than 6/60 (20/200) appear to have had better outcomes.

These data seem to argue for a potential role of this procedure in selected cases. However, without a randomised controlled trial and a larger number of patients it is difficult to assess the efficacy of the procedure for this indication.

Lamina puncture

This is transvitreal optic disc surgery to create a perivascular opening in the lamina cribrosa. This aims to release the postulated constriction of the central retinal vein by the surrounding connective tissue at the level of the lamina cribrosa. The resultant increase in luminal diameter of the central retinal vein may allow the passage of the thrombus or relieve the pressure predisposing to thrombus formation. Alternatively, it may allow sufficient blood flow at the level of the lamina cribrosa to permit increased retinal perfusion, even if the thrombus is not dislodged or mechanically expressed. Thus far the technical feasibility has been established only on human cadaver and enucleated pig eyes.56 Until in vivo trials are performed it is not possible to determine if this will lead to success.

Chorioretinal venous anastomosis

First described almost 50 years ago by Verhoeff,61 chorioretinal anastomosis allows blood to bypass the occluded vein into the choroidal circulation. It is thought that vision is improved by a reduction in macular oedema and in progression to an ischaemic status.

This technique has been applied to both BRVO and CRVO and may be done either by laser or surgery. Patient numbers for BRVO are too low for meaningful evaluation.
Chorioretinal venous anastomosis by laser
The effect of laser induced chorioretinal anastomosis depends on the type of RVO and the establishment of a successful anastomosis. The best results of this procedure have been found in non-ischaemic CRVO where approximately one third to one half of patients develop a functionally effective chorioretinal anastomosis. Chorioretinal venous anastomosis in ischaemic eyes is very difficult to achieve, perhaps because of the presence of endothelial cell damage. Although a successful anastomosis prevents further progression towards ischaemia, the visual results of chorioretinal anastomosis are poor. Complications of this procedure include vitreous haemorrhage (42%), choroidal neovascularisation (21%), and preretinal fibrosis (12%). Complications are magnified in ischaemic CRVO.

In order to reduce the risk of neovascular complications, chorioretinal venous anastomosis should perhaps be limited to non-ischaemic CRVO and patients treated by this technique should be closely followed up. Optimal timing of intervention is unclear but one study suggests it should be less than 4 months, since the average time for the anastomosis to become functional is 6.7 weeks and because an average of 2.1 attempts are needed to establish an anastomosis. Much work is needed in this field. The ophthalmoscopic and angiographic criteria required to determine the presence of chorioretinal anastomosis have not yet been well described. Further evaluation of the laser power required to produce an anastomosis is necessary. Reasons why some eyes respond to laser by forming anastomosis while others develop a fibrovascular response are unclear. Factors that determine whether or not an anastomosis forms include patient’s age, presence of optic nerve head collaterals, the presence of an underlying choroidal vein near the treatment site, and degree of intravascular pressure elevation in the obstructed vein.

Chorioretinal venous anastomosis by surgery
Given the unpredictable yield of laser induced chorioretinal anastomosis, surgical methods are being evaluated. In a pilot study pars plana vitrectomy was followed by slit-like incisions through Bruch’s membrane adjacent to a major branch of a retinal vein in each quadrant. Small pieces of 5/0 madrilene suture were placed over the vein and inserted into these incision sites to maintain its patency and promote the formation of collaterals. Endolaser treatment was then performed around the incision site followed by panretinal laser photoagulation.

Of 16 attempted chorioretinal venous anastomosis sites, 10 were functioning. In all cases there was proliferation of avascular fibrous tissue. Final visual acuity was better in three eyes. Larger trials are awaited.

INTERVENTIONS FOR BRVO
Steroids
Similar to their use in CRVO, the use of intravitreal triamcinolone has recently been advocated in BRVO patients and, in a controlled study, was shown to significantly improve visual acuity in patients with chronic macular oedema. Further work is awaited. The risks of this treatment are comparable to those for CRVO.

Isosvolaem haemodilution
Chen et al demonstrated positive results for isosvolaemic haemodilution given up to 3 months after BRVO in a randomised controlled study; 18 patients were treated for 6 weeks and compared to 16 control patients. After 1 year of follow up the visual acuity in the treated group improved compared to the controls (p = 0.03). Final visual acuities were 6/12 and 6/24 for treated and untreated patients, respectively. At the 3 month follow up argon laser treatment was given for macular oedema and vision less than 6/12, neovascularisation or capillary non-opefuration greater than 5 disc diameters. There was no significant difference between cases and controls requiring laser treatment. It therefore appears that isosvolaemic haemodilution may be of benefit in both CRVO and BRVO.

Vitrectomy
The vitreous is postulated to have a role in the pathogenesis of neovascularisation and macular oedema, which may complicate BRVO and its removal may help in the management of these sight threatening complications.

An intact vitreoretinal surface provides a scaffold for neovascularisation. The vitreous allows angiogenic factors from the ischaemic retina to diffuse into it and traction through the vitreous fibres on the Muller cells of the retina predisposes to cystoid macular oedema. Animal studies on vitrectomised and non-vitrectomised eyes show that inducing a BRVO in non-vitrectomised eyes results in retinal hypoxia, whereas BRVO induced in vitrectomised eyes produced no change in retinal oxygen tension.

It is postulated that vitrectomy allows access of oxygenated aqueous to the inner retina, thereby improving macular oedema, reducing ischaemia, and improving vision. Pars plana vitrectomy has been shown to reduce macular oedema and restore the normal foveal contour but there was no significant change in best corrected visual acuity.

Visual improvement occurs after vitrectomy for vitreous haemorrhage or retinal detachment complicating BRVO. This is an established treatment for these complications. No studies are available on vitrectomy being performed before the development of these complications.

Arteriovenous crossing sheathotomy
Venous compression in BRVO may be relieved by dividing the common adventitial sheath that surrounds retinal arterioles and venules at arteriovenous (A-V) crossing points.

An initial case report in a 54 year old woman with a 3 week history of BRVO showed visual improvement from 6/60 (20/200) to 6/7.5 (20/25) after 8 months’ follow up. However, the re-perfusion status was not indicated. In a small uncontrolled prospective series of 15 eyes, Opremcak and Bruce reported results after A-V sheathotomy with BRVO and 6/21 (20/70) or worse Snellen visual acuity. In all patients, intraoperative sheath decompression was achieved, resulting in clinical improvements in retinal haemorrhages and retinal perfusion. Postoperative visual acuity improved in 10 of 15 patients (67%) with an average of four lines of vision gained. Nevertheless, vision did not improve in three patients despite surgical success and resolution of fundus changes. This was attributed by the authors, to a postoperative IOP rise. Two patients developed vascular bleeding as a result of an anatomical variation in vessel configuration at the A-V crossing point of the BRVO. The authors did not report visual recovery to correlate with initial visual acuity, duration of the BRVO, severity of intraretinal haemorrhage, oedema or ischaemia, or with final visual acuity.

In a controlled prospective study 43 patients with BRVO were treated with A-V decompression while 25 patients who refused surgery acted as controls. The mean VA improved from 0.35 to 0.16 on the logMAR scale; 26 patients (60%) gained at least two lines of vision and 12 patients (28%) gained at least four lines of vision. After 6 weeks’ follow up, macular oedema and retinal haemorrhages had resolved. Patients with the most improvement also showed angiographic improvements in venous perfusion, whereas four patients with completely occluded vessels showed the worst functional results. Despite visual improvement, capillary
reperfusion was only observed in four eyes. Overall, the functional outcome were significantly better in patients with A-V decompression than controls and outcomes were more favourable in patients under 65 years of age. This may be explained by the advanced sclerotic changes of the blood vessels in older patients.

Retrospective studies have similarly shown benefits from A-V sheathotomy. Although the case series are small, visual improvements of 80% have been demonstrated in patients with preoperative vision of 6/60 (20/200). These studies have follow ups ranging from 5–7 years. Cahill et al report a complete resolution of macular oedema and a significant increase in visual acuity in one third of patients after A-V sheathotomy. However, in the majority of cases a reduction of oedema was not associated with improved visual acuity.

The optimum timing of intervention is unclear. Some investigators have reported successful surgical intervention after as long as 6 months. In other studies if the preoperatively duration of BRVO was 3 months, the results were worse than those cases where a shorter interval occurred between BRVO and surgery.

Reported complications are few but include cataract, nerve fibre layer defects, haemorrhage, retinal tear, postoperative gliosis, and retinal detachment.

Although preliminary results are encouraging, further questions remain. What is the time window in which decompression would give optimal results? Will A-V sheathotomy be more effective if performed before the thrombus becomes organised? The success of A-V sheathotomy may be partly attributed to the vitrectomy performed at the same time which resulted in preventing neovascularisation and persistent macular oedema. Further investigations are required to better define what degree of functional deterioration caused by BRVO mandates surgical intervention. It may be that a combination approach is needed—such as A-V sheathotomy and injection of thrombolytic into the occluded vein, which resulted in thrombus release in 28% cases and significant correlation with early surgery and better final visual acuity.

CONCLUSION

Retinal vein occlusions are the second most common sight threatening vascular disorder. Despite this, our therapeutic armamentarium for functional improvement has been very limited. We are now moving into a new era where many novel interventional treatments have been described for RVOs.

There are three main deficiencies in the evidence we currently have for interventional treatments in RVO. The main observation is the lack of large well designed prospective randomised controlled trials. Pilot studies on interventional treatments for vein occlusion seem promising but all are non-randomised and uncontrolled studies in small numbers of patients. Randomised controlled trials remain the gold standard of research methodology and provide the best indication of treatment effect. Until these are available many ophthalmologists will be reluctant to change their practice.

Secondly, there is lack of long term follow up in many studies. While some interventions (for example, intravitreal steroids) seem to have a temporary effect, we do not know the long term outcomes of other measures. The third issue to address is optimal timing of intervention and patient selection. Ideally, early intervention would be best before thrombus organisation or further ischaemic damage occurs but the effective treatment window remains obscure. Most interventions appear to be more successful in non-ischaemic vein occlusions but further clarification is necessary.

At present the evidence to date does not support any therapeutic benefit from radial optic neurotomy, optic nerve sheath decompression or A-V crossing sheathotomy in eyes with vein occlusion. Furthermore, the potential complications outweigh any benefits. The use of isovolemic haemodilution requires careful patient selection and should be avoided in patients with concurrent cardiovascular, renal, or pulmonary disease. Unfortunately, as a significant number of patients with vein occlusion have concurrent cardiovascular morbidity, and the benefits are limited, we would not recommend haemodilution.

Secondly, with the available evidence we have we suggest that the use of intravitreal steroids may be a beneficial early intervention in carefully selected patients with CRVO or BRVO. Intravitreal steroids have been evaluated in non-randomised comparative studies and have been shown to significantly be better than no treatment, and although the steroid effect is not permanent it may prevent early photoreceptor damage from macular oedema and improve long term prognosis. Anti-VEGF agents, which are gaining popularity in treatment of choroidal neovascularisation, may have a role in future.

Vitrectomy with intravenous thrombolysis with t-PA seems to offer the most promising option for CRVO. This procedure seems to give the best outcome with fewer side effects. It also seems the most physiological of all the presently suggested options. Similarly, although not tried yet, vitrectomy, A-V sheathotomy combined with intravenous t-PA may offer benefits in BRVO.

Despite uncertainty and open questions, surgical interventions are likely to be a therapeutic option for RVO in the future. Vein occlusions occur at a sufficiently high frequency for future prospective randomised controlled studies to be conducted so that we can truly evaluate the role of each therapeutic modality both individually and in combination.

Authors’ affiliations
H Shahid, Prince Charles Eye Unit, King Edward VII Hospital, Windsor SL4 3DP, UK
P Hossain, Department of Ophthalmology, Southampton General Hospital, Southampton SO16 6YD, UK
W W Amoaku, Academic Department of Ophthalmology, University of Nottingham, Eye, Ear, Nose and Throat Centre, Queen’s Medical Centre, Nottingham NG7 2UH, UK

Proprietary interest: none.
Competing interests: none declared

REFERENCES


